Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 43.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,263,353 shares of the company's stock after acquiring an additional 382,608 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 1.84% of Amylyx Pharmaceuticals worth $4,775,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in AMLX. Y Intercept Hong Kong Ltd bought a new position in Amylyx Pharmaceuticals in the fourth quarter worth approximately $56,000. Blue Trust Inc. lifted its stake in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock valued at $26,000 after purchasing an additional 4,883 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Amylyx Pharmaceuticals by 144.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company's stock worth $455,000 after purchasing an additional 83,048 shares during the period. Barclays PLC raised its stake in shares of Amylyx Pharmaceuticals by 91.1% in the third quarter. Barclays PLC now owns 84,572 shares of the company's stock valued at $274,000 after acquiring an additional 40,319 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Amylyx Pharmaceuticals by 17.5% during the 3rd quarter. Geode Capital Management LLC now owns 551,039 shares of the company's stock worth $1,786,000 after purchasing an additional 82,173 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.
Amylyx Pharmaceuticals Trading Up 2.2 %
Shares of NASDAQ AMLX traded up $0.08 during mid-day trading on Thursday, reaching $3.73. The company had a trading volume of 366,167 shares, compared to its average volume of 1,397,328. The stock has a market cap of $330.49 million, a P/E ratio of -0.98 and a beta of -0.51. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $7.27. The firm has a 50 day simple moving average of $3.50 and a two-hundred day simple moving average of $3.96.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. On average, equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.
Insiders Place Their Bets
In related news, CEO Joshua B. Cohen sold 11,851 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the transaction, the chief executive officer now owns 3,201,247 shares of the company's stock, valued at $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Justin B. Klee sold 7,471 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the transaction, the chief executive officer now owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,169 shares of company stock valued at $97,274. Insiders own 11.70% of the company's stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $7.33.
Get Our Latest Stock Analysis on AMLX
About Amylyx Pharmaceuticals
(
Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Further Reading
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
